Optimization of a broad and potent decoy receptor for SARS-associated viruses
Optimization of a broad and potent decoy receptor for SARS-associated viruses
批准号:
10258005
负责人:
Kui Kiu Chan
金额:
$9.6万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2022-11-30
关键词:
2019-nCoVACE2AddressAdrenal Cortex HormonesAdult Respiratory Distress SyndromeAffinityAmino AcidsAngiotensin IIAngiotensinsAnimal ModelAnimalsBindingBinding SitesBiologicalBiotechnologyBlocking AntibodiesCOVID-19COVID-19 pandemicCOVID-19 treatmentCell membraneCellsChimeric ProteinsChiropteraClinicClinicalCodon NucleotidesCompetitive BindingComplexCoronavirusCoupledDataDevelopmentDexamethasoneDiseaseDisease OutbreaksDrug TargetingEngineeringEpitopesEscape MutantFDA approvedFlow CytometryFreeze DryingFreezingFutureGenetic DriftGenetic RecombinationHalf-LifeHeartHumanIgG1IllinoisIn VitroInfectionInflammationInvestigational DrugsLibrariesLungLung InflammationMeasurementMedicalMolecular ConformationMonoclonal AntibodiesMusMutagenesisMutateMutationNoiseNucleotidesPatientsPeptidesPharmaceutical PreparationsPolymerasePositioning AttributePropertyProtein EngineeringProteinsPublishingResistanceSARS coronavirusSARS-CoV-2 infectionSafetySatellite VirusesScanningSerumSevere Acute Respiratory SyndromeSiteSourceSpecificityStructureSymptomsTemperatureTestingTherapeuticToxicologyUniversitiesVariantVendorViralVirusVirus Replicationbasebetacoronaviruscommercializationdeep sequencingdesigndrug developmenthuman coronavirusimmunogenicitylead candidatelead optimizationlung injurymutantnanomolarneutralizing antibodyneutralizing monoclonal antibodiesnucleoside analogolder patientpandemic diseasepathogenpeptide hormonephysical propertypreventprogramsprotective effectreceptorreceptor bindingremdesivirresistance mutationstability testingtissue culturezoonotic coronavirus
中文摘要
摘要
英文摘要
ABSTRACT
The spike protein (S) of SARS coronavirus 2, the pathogen responsible for COVID-19, binds angiotensin-
converting enzyme 2 (ACE2) as an entry receptor, triggering conformational changes in S that drive fusion of
the viral envelope and host cell membrane. Infection is inhibited by neutralizing antibodies that block the
ACE2-binding site on S, yet escape mutations in S rapidly emerge towards monoclonal antibodies in tissue
culture. Furthermore, monoclonal antibodies are generally strain specific, and many do not recognize with high
affinity both human SARS-CoV-1 and SARS-CoV-2, yet alone exotic bat betacoronaviruses that are a reservoir
for future outbreaks. As an alternative for biologic drug development, we have used deep mutagenesis to
guide the engineering of an exceptionally broad soluble decoy receptor that binds with tight picomolar/low-
nanomolar affinity to S from all bat and human SARS-associated coronaviruses tested. The engineered decoy
potently neutralizes authentic SARS-CoV-1 and SARS-CoV-2 with an efficacy that rivals monoclonals under
commercial development, and has desirable properties for manufacture at scale. The engineered decoy also
catalytically converts angiotensin II to vasodilatory peptide products that might directly address symptoms of
COVID-19, providing us with a unique potential therapeutic that has dual mechanisms of action. Our proposal
investigates whether the SARS-CoV-2 spike can mutate to escape neutralization by the engineered decoy
receptor, and addresses final optimization of the engineered protein as an IgG1-Fc fusion before advancement
to an IND-enabling program. For SARS-CoV-2 to become resistant to the engineered decoy, mutations in S
must decrease affinity to the decoy while maintaining binding to human ACE2 receptors. To identify such S
variants, we have used saturation mutagenesis of the receptor-binding domain coupled with a selection for
tight binding to wild type ACE2 in the presence of competing soluble decoy. Following deep sequencing, a
small number of mutations were found to be enriched, but it is unclear whether any of these mutations do
indeed preferentially bind wild type ACE2 and if so, to what degree they have achieved specificity. Based on
this preliminary data, (Aim 1) we will validate whether mutations in S can be found that discriminate between
human ACE2 and the engineered decoy, and characterize the variants for their affinities and expression levels.
Thus far, we can conclude that possible resistance mutations appear to be very rare and generally require
more than one nucleotide change within a codon, but further quantitative characterization is needed.
Simultaneously, (Aim 2) we will rapidly optimize fusions of the engineered decoy with the Fc region of IgG1 for
enhanced serum stability. Our current IgG1-fusion construct (which was based on rational, structure-guided
design) is highly expressed, stable and binds SARS-CoV-2 S with picomolar affinity. We will finalize
optimization of the protein by scanning suitable fusion sites between the engineered decoy and IgG1,
assessing protein quality by activity, stability and expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimization of a broad and potent decoy receptor for SARS-associated viruses
-
批准号:10731465
-
项目类别:
-
资助金额:$16.06万
-
财政年份:2021
-
负责人:Kui Kiu Chan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
-
批准号:JCZRLH202600625
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
-
批准号:2026JJ50619
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:翁春艳
-
依托单位:
AURKA介导ACE2磷酸化修饰调控内皮细胞衰老在低氧性肺动脉高压中的作用及机制研究
-
批准号:82570085
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:沈慧
-
依托单位:
牛蒡叶倍半萜成分群激活ACE2/Ang1-7/MasR轴调控血管内皮—周细胞互作促缺血性脑卒中血管正常化机制研究
-
批准号:82404910
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2024
-
负责人:郝单丽
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:
-
依托单位:
ACE2通过AMPK/SIRT3调控线粒体代谢改善盐敏感性高血压肾脏纤维化的机制
-
批准号:82460087
-
项目类别:地区科学基金项目
-
资助金额:33.00万元
-
批准年份:2024
-
负责人:赵宇
-
依托单位:
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
-
批准号:Y24H280055
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:颜美秋
-
依托单位:
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
-
批准号:82330111
-
项目类别:重点项目
-
资助金额:220万元
-
批准年份:2023
-
负责人:刘刚
-
依托单位:
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
-
批准号:82373169
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:顾良友
-
依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
-
批准号:32300137
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:陈静
-
依托单位: